Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

NCT04513028 is registered in ClinicalTrials.gov with Kelly McMasters as lead sponsor.

NCT NCT04513028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04513028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
Lead sponsor
Kelly McMasters
Phase
Not applicable
Overall status
Recruiting
Start date
November 3, 2020
Completion date
January 15, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii, melanoma stage iv